Bisphosphonate therapy for women with breast cancer and at high risk for osteoporosis

Journal of the National Medical Association

Volumn 99, Issue 1, 2007, Pages 35-45

  Morris, Gloria J ^a,b   Mitchell, Edith P ^a,b  

^a Thomas Jefferson University Hospital ^*

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Bisphosphonates; Breast cancer; Osteoporosis

Indexed keywords

ALENDRONIC ACID; AMGN 007; ANABOLIC AGENT; ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CLODRONIC ACID; CONJUGATED ESTROGEN; DENOSUMAB; DOXORUBICIN; ESTRADIOL; ESTROGEN; ETIDRONIC ACID; FLUINDOSTATIN; GEMCITABINE; IBANDRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; PACLITAXEL; PAMIDRONIC ACID; PARATHYROID HORMONE RELATED PROTEIN; PARATHYROID HORMONE[1-34]; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN DERIVATIVE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN CITRATE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLEDRONIC ACID;

BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RISK; CARDIOVASCULAR RISK; DEEP VEIN THROMBOSIS; DRUG MECHANISM; ESOPHAGITIS; FEMALE; FRACTURE; HIGH RISK PATIENT; HIGH RISK POPULATION; HOT FLUSH; HUMAN; HYPERCALCEMIA; LEG CRAMP; LOW DRUG DOSE; MYALGIA; NAUSEA; NOSE CONGESTION; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; OVARY FUNCTION; OVARY INSUFFICIENCY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW;

BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; OSTEOPOROSIS;

EID: 33846642249     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Roodman GD. Mechanism of bone metastases. N Engl J Med. 2004;350 (16):1655-1664.
2. Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology. 2005;19(5):651-658.
3. Van Poznak C, Sauter NP. Clinical management of osteoporosis in women with a history of breast carcinoma. Cancer. 2005;104(3):443-456.
4. Mauck KF, Clarke BL. Diagnosis, screening, prevention, and treatment of osteoporosis. Mayo Clin Proc. 2006;81(5):662-672.
5. Hillner BE, Ingle JK, Chlebowski RT, et al. American Society of Clinical Oncology 2003 Update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21(21):4042-4057.
6. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. NIH Consens State 2000;17:1-45.
7. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry. JAMA. 2002;288(15):1889-1897.
8. Quandt SA, Thompson DE, Schneider DL, et al. Fracture Intervention Trial Research Group. Effect of alendronate on vertebral fracture risk in women with bone mineral density T Scores of -1.6 to -2.5 at the femoral neck: the fracture intervention trial. Mayo Clin Proc. 2005;80(3):343-349.
9. Bone Health and Osteoporosis: a Report of the Surgeon General. Rockville, MD; 2004. U.S. Department of Health and Human Services publication, 436 pp.
10. Bell NH, Bilezikian JP, Bone HG III, et al. Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women. J Clin Endocrin Metab. 2002;87(6):2792-2797.
11. Bohannon AD. Osteoporosis and African American women. J Womens Health Gend Based Med. 1999;8(5):609-615.
12. Alam NM, Archer JA, Lee E. Osteoporotic fragility fractures in African Americans: under-recognized and undertreated. J Natl Med Assoc. 2004;96(12):1640-1645.
13. Aloia JF, Vaswani A, Yeh JK, et al. Risk for osteoporosis in black women. Calcif Tissue Int. 1996;59(6):415-423.
14. Kessenich CR. Osteoporosis and African-American women. Womens Health Issues. 2000;10(6):300-304.
15. Luckey MM, Wallenstein S, Lapinski R, et al. A prospective study of bone loss in African-American and white women-a clinical research center study. J Clin Endocrin Metab. 1996;81(8):2948-2956.
16. Wilkins CH, Goldfeder JS. Osteoporosis screening is unjustifiably low in older African-American women. J Natl Med Assoc. 2004;96(4):461-467.
17. U.S. Preventive Services Task Force. Screening for osteoporosis in post-menopausal women: recommendations and rationale. Ann Intern Med. 2002;137:526-528.
18. Epstein, S. The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy. Mayo Clin Proc. 2005;8(3):379-388.
19. Green JR. Bisphosphonates: preclinical review. Oncologist. 2004;9(suppl 4):3-13.
20. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 1994;9(5);745-751,
21. Reszka AA, Rodan GA. Bisphosphonate mechanism of action. Curr Rheumatol Rep. 2003:5(1):65-74.
22. Larsen PR, Kronenberg HM, Polonsky KS, et al, eds. Treatment of Osteoporosis. Williams Textbook of Endocrinology, 10th ed. St. Louis, MO: WB Saunders Co., an Imprint of Elsevier Science; 2003:1385-1393.
23. Yoneda T, Hashimoto N, Hiraga T. Bisphosphonate actions on cancer. Calcif Tissue Int. 2003;73(4):315-318.
24. Diel IJ. Antitumor effects of bisphosphonates: first evidence and possible mechanisms. Drugs. 2000;59(3):391-393.
25. Hiraga T, Williams PJ, Ueda A, et al. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res. 2004;10(13):4559-4567.
26. Budman DR, Calabro A. Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents. Oncology. 2006;70(2):147-153.
27. Vogt U, Bielawski KP, Bosse U, et al. Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/methotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep. 2004;12(5):1109-1114.
28. Neville-Webbe HL, Evans CA, Coleman RE, et al. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol.2006;27(2):92-103.
29. Jagdey SP, Coleman RE, Shipman CM, et al. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 2001;84(8):1126-1134.
30. Woodward JK, Neville-Webbe HL, Coleman RE, et al. Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro. Anticancer Drugs. 2005;16(8):845-854.
31. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, et al. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer. 2005;113(3):364-371.
32. Vincenzi B, Santini D, Dicuonzo G, et al. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res. 2005;25(3):144-151.
33. Conte PF, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist. 2004;9(suppl 4):28-37.
34. Body JJ. Bisphosphonates in metastatic bone disease: renal safety matters. Oncologist. 2005;10(suppl 1):1-2.
35. Hortobagyi GN, Theriault RL, A Lipton, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol. 1998;16(6):2038-2044.
36. Guarneri V, Donati S, Nicolini M, et al. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years. Oncologist. 2005;10(10):842-848.
37. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006;17:897-907.
38. Van Poznak CH, Estilo CL, Sauter NP, et al. Osteonecrosis of the jaw in patients with metastatic breast cancer. Proceedings of the San Antonio Breast Cancer Symposium, Breast Cancer Res Treat. 2004;88:abstract 3057.
39. Durie BGM, Katz M, Crowley J. Osteonecrosis of the Jaw and Bisphosphonates. N Engl J Med. 2005;353(10):99-100.
40. Woo S-B, Hande K, Richardson PG. Osteonecrosis of the Jaw and Bisphosphonates. N Engl J Med. 2005;353(10):100.
41. Maerevoet M, Martin C, Duck L. Osteonecrosis of the Jaw and Bisphosphonates. N Engl J Med. 2005;353(10):100-101.
42. Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144(10):753-761.
43. Carter GD, Goss AN. Bisphosphonates and avascular necrosis of the jaws. Austr Dent J. 2003;48(4):268.
44. Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr. 2000;10:159-178.
45. Guise TA, Yin JJ, Mohammad KS. Role of enodthelin-1 in osteoblastic bone metastases. Cancer. 2003;97(suppl):779-784.
46. Kasperk CH, Borcsok K, Schairer HU, et al. Endothelin-1 is a potent regu-lator of human bone cell metabolism in vitro. Calcif Tissue Int. 1997;60:368-374.
47. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995;1:944-949.
48. Berenson JR, Lipton A. Use of bisphosphonates in patients with metastatic bone disease. Oncology. 1998;12(110):1573-1579.
49. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998;16(2):593-602.
50. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98(8):1735-1744.
51. Small EJ, Smith MR, Seaman JJ, et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003;21(23):4277-4284.
52. Saad F, Gleason DM, Murray R, et al. Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458-1468.
53. Saad F, Gleason DM, Murray R, et al. Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879-882.
54. Kelly WK, Steineck G. Bisphosphonates for men with prostate cancer: sifting through the rubble. J Clin Oncol. 2003;21(23):4261-4262.
55. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21:3150-3157.
56. Rosen LS, Gordon D, Tchekmedyian S, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004;100:2613-2621.
57. Lipton A, Small E, Saad F, et al. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer. Investigation 2002;20:(suppl 2):45-54.
58. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996;335(24):1785-1791.
59. Gordon DH. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials. Clin Breast Cancer. 2005;6(2):125-131.
60. Body JJ, Diel IJ, Lichinitser MR, et al. MF 4265 Study Group. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol. 2003;14(9):1399-1405.
61. Tripathy D, Lichinitser M, Lazarev A, et al. MF 4434 Study Group. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: Efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol. 2004;15(5):743-750.
62. Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomized, placebo-controlled phase III studies. Br J Cancer. 2004;90(6):1133-1137.
63. Bergstrom B, Lichinitser MR, Andreeva N, et al. Intravenous ibandronate 15-minute infusion followed by daily oral ibandronate for metastatic bone disease: bone marker data. Breast Cancer Res Treat. 2005;94(1):abstract 6034.
64. Body JJ, Lichinitser MR, Tjulandin SA, et al. Safety of oral ibandronate and intravenous zoledronic acid in breast cancer patients with metastatic bone disease. Breast Cancer Res Treat. 2005;94(1):abstract 6035.
65. Heras P, Hatzolpoulos A, Mitsibounas D. Efficacy and safety of intravenous ibandronate 6 mg infused over 15 minutes: results from a 2-year study of breast cancer patients with metastatic bone disease. Breast Cancer Res Treat. 2005;94(1):abstract 6037.
66. Body JJ, Diel IJ, Bell R, et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain. 2004;111(3):306-312.
67. Body JJ, Bergstrom B. Improving metastatic bone pain management with ibandronate in patients with breast cancer. Proceedings of the San Antonio Breast Cancer Symposium, Breast Cancer Res Treat. 2004;88 (suppl 1):abstract 3065.
68. Body J, Lichinitser M, Tjulandin S, et al. Effect of oral ibandronate versus intravenous (i.v.) zoledronic acid on markers of bone resorption in patients with breast cancer and bone metastases: results from a comparative phase III trial. J Clin Oncol. 2005 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2005;23(16S)(July suppl):534.
69. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005;23(15):3314-3321.
70. Heidenreich C, Ohlmann U, Engelmann H. Ibandronate in the management of painful osseous metastases due to hormone refractory prostate cancer. American Society of Clinical Oncology, 2005 Prostate Cancer Symposium, abstract 279.
71. Diel IJ. Bisphosphonates in the prevention of bone metastases: current evidence. Semin Oncol. 2001;28(4 suppl 11):75-80.
72. Jaschke A, Bastert G, Solomayer EF, et al. Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow-a longtime follow-up. J Clin Oncol. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004;22(14S)(July 15 suppl):529.
73. Saarto T, Vehmanen L, Blomqvisf C, et al. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. J Clin Oncol. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004;22(14S) (July 15 suppl):527.
74. Powles T, McCloskey E, Kurkilahti M. Oral clodronate for adjuvant treatment of operable breast cancer: Results of a randomized, double-blind, placebo-controlled multicenter trial. J Clin Oncol. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004:22(14S)(July 15 suppl):528.
75. McCloskey EV, Paterson AHG, Powles TJ. Effects of oral clodronate (Bonefos) therapy on bone turnover and skeletal metastases in women with primary breast cancer. Breast Cancer Res Treat. 2005;94(1):abstract 43.
76. McCloskey E, Paterson AH, Powles TJ. Oral clodronate maintains bone mass in women with primary breast cancer. J Clin Oncol. 2005 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 2005;23(16S)(July suppl):535.
77. Black DM, Bilezikian JP, Ensrud KE, et al, for the PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med. 2005;353(6):555-565.
78. Cosman F, Nieves J, Woelfert L, et al. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med. 2005;353(6):566-575.
79. Howell A on behalf of the ATAC Trialists' Group. ATAC ('Arimidex', Tamoxifen, Alone or in Combination) completed treatment analysis: anastrozole demonstrates superior efficacy and tolerability compared with tamoxifen. Proceedings of the 27th Annual San Antonio Breast Cancer Symposium, Breast Cancer Res Treat. 2004;88(suppl 1):abstract 1. San Antonio Breast Cancer Symposium [website].
80. Jakesz R, Kaufmann M, Gnant M, et al. Benefits of switching post-menopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3, 123 women enrolled in the ABCSG trial 8 and the ARNO 95 trial. Breast Cancer Res Treat. 2004;88(suppl 1),S7(abstract 2).
81. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer. Status Report 2004. J Clin Oncol. 2004;255(23):619-629.
82. Baum M, Buzdar A, Cuzick J, et al. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of post-menopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003;98(9):1802-1810.
83. Coombes RC, Hall E, Gibson LJ, et al; Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350(11):1081-1092.
84. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349(19):1793-1802.
85. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(26):2747-57.
86. Lønning PE, Geisler J, Krag LE, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol. 2005;23(22):5126-5137.
87. Brufsky A, Harker G, Beck T, et al; Z-FAST Study Group. Zoledronic acid (ZA) for prevention of cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant Letrozole (Let): Preliminary results of the Z-FAST trial. Proceedings of the San Antonio Breast Cancer Symposium, Breast Cancer Res Treat. 2004; (suppl 1) abstract 1114.
88. Brufsky A, Harker W, Beck J, et al; The Z-FAST Study Group. Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant Letrozole (Let): 12 mos BMD results of the Z-FAST trial. J Clin Oncol. 2005 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 2005; Vol No (July Supplement): abstract 533.
89. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol. 2001;19(14):3306-3311.
90. Delmas PD, Balena R, Confravreux E, et al. Bisphosphonate risedronafe prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol. 1997;15(3):955-962.
91. Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003;18(6):1051-1056.
92. Gnant M, Hausmaninger H, Samonigg H, et al. Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer: results of a randomized multicenter trial. Proceedings of the San Antonio Breast Cancer Symposium. Breast Cancer Res Treat. 2002;abstract 12.
93. Gnant M, Jakesz R, Mlineritsch B, et al; the ABCSG Austrian Breast and Colorectal Cancer Study Group. Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen-bone density subprotocol results of a randomized multicenter trial (ABCSG-12). Proceedings of the San Antonio Breast Cancer Symposium, Breast Cancer Res Treat. 2004;88:abstract 6.
94. Lara-Smalling AA, Shelton AJ, Douglas TC. Osteoporosis among perimenopausal African-American women: the relationship between sources of information and levels of knowledge about osteoporosis. J Natl Black Nurses Assoc. 2004;15(2):40-47
95. Mudano AS, L Casebeer, F Patino, et al. Racial disparities in osteoporosis prevention in a managed care population. South Med J. 2003;96(5):445-451.
96. Unson CG, Fortinsky R, Prestwook K, et al. Osteoporosis medications used by older African-American women: effects of socioeconomic status and psychosocial factors. J Community Health. 2005;30(4):281-287.
97. Wallace LS, Ballard, JE, Holiday D. Evaluation of decision rules for identifying low bone density in postmenopausal African-american women. J Natl Med Assoc. 2004;96(3):290-296.
98. Lipton A. Toward New Horizons: the Future of Bisphosphonate Therapy. Oncologist. 2004;9(suppl 4):38-47.
99. Lipton A, Costa L, Ali S, et al. Use of markers of bone turnover for monitoring bone metastases and the response to therapy. Semin Oncol. 2001;28(4 suppl 11):54-59.
100. Brown J, Cook R, Coleman RE, et al. The role of bone turnover markers in predicting clinical events in metasfafic bone disease. J Clin Oncol. Proceedings of the American Society of Clinical Oncology. 2003;22:738 [abstract 2969].
101. Coleman RE, Cook R, Major P, et al. Why is zoledronic acid (Z) superior to pamidronate (P) for bone metastases from breast cancer (BC) but equivalent in mujtiple myeloma (MM)? J Clin Oncol. Proceedings of the American Society of Clinical Oncology. 2003;22(47):abstract 187.
102. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005;97(1):59-69.
103. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005;23(22): 4925-4935.
104. Roodman GD. High bone turnover markers predict poor outcome in patients with bone metastases. J Clin Oncol. 2005;23(22):4821-4822.
105. Lipton A, Hei Y, Coleman R, et al. Suppresion of bone turnover markers by zoledronic acid and correlation with clinical outcome. J Clin Oncol. 2005 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 2005:23, (16S)(July suppl):532.
106. Hofbauer LC, Kuhne CA, Viereck V. The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact. 2004;4(3):268-275.
107. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotogerin/RANKL/RANK system for bone and vascular disease. JAMA. 2004;292(4):490-495.
108. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose, placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004;19:1059-1066.
109. Peterson MC, Martin SW, Stouch B, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of AMG162, a fully human monoclonal antibody to Receptor Activator of NF kappa B Ligand (RANKL), following a single subcutaneous dose to patients with cancer-related bone lesions. J Clin Onco., 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 2004;22(14S)July 15 suppl):8106.
110. Body JJ, Greipp P, Coleman RE, et al. A phase I study of AMGN-0007, a recombinant osteoprotogerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer. 2003;97(3):887-892.
111. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344;1434-1441.
112. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001;296:235-242.